ISSSTE Strengthens Medicine Distribution Through CENADI

ISSSTE is scaling up its national medicine distribution through CENADI, which stores nearly 50 million units and supplies 787 medical facilities monthly, while intensifying supplier oversight to address reported shortages. This move aims to support Mexico's healthcare procurement and pharmaceutical sectors as public institutions work to close supply gaps following the 2023 centralized purchasing overhaul. 

The Institute of Security and Social Services for State Workers (ISSSTE) is reinforcing the distribution of medicines across its national pharmacy network by expanding operations at its National Distribution Center (CENADI) and tightening its monitoring of supplier deliveries. The institute reports that its central warehouse now holds close to 50 million pieces across more than 1,000 medicine codes and distributes roughly 17 million units monthly to 787 medical units nationwide.

The announcement comes as Martí Batres, Director General, ISSSTE, says supply has improved substantially in recent months, while acknowledging shortfalls persist. "The supply of medicines at ISSSTE has improved quite a bit in recent months. We still have work to do, that is true; however, we have a notable improvement," he says, adding that the main objective is for members to receive the medications they require. The remark frames the announcement as a description of operational progress rather than a claim that availability gaps have been fully resolved.

ISSSTE's push follows a broader effort across Mexico's public health institutions to close medicine supply gaps that intensified after a 2023 procurement overhaul centralized federal drug purchasing. Batres has separately reported that pharmacy availability across the institute averages 97%, with no facility falling below 90% and 592 of its pharmacies operating between 95% and 100% supply. The same report noted that more than 90 million units were delivered to the national distribution center in late 2025 and early 2026, pointing to a sustained increase in warehouse throughput ahead of the latest announcement.

CENADI, located in the State of Mexico, functions as the primary node from which medicines and supplies are routed to pharmacies and warehouses across the country. Its inventory levels and monthly dispatch volume illustrate the scale of the logistics operation, though the figures alone do not indicate how completely individual prescriptions are being filled at the pharmacy counter. CENADI received 56 million pieces of medicines and 16 million pieces of healing materials during the first quarter of 2026 alone, underscoring the growing volume moving through the facility as the institute works toward full coverage.

When a pharmacy reports a shortage of a specific medicine code, ISSSTE says it accelerates shipment from CENADI's inventory while simultaneously pressing suppliers to speed up pending deliveries. This two-track approach combines redistribution of existing central stock with active oversight of contracted providers, reflecting a recognition that internal logistics alone cannot guarantee continuity of supply if inputs do not arrive from manufacturers on schedule. The institute has not disclosed average response times between a shortage report and restocking, nor the criteria used to prioritize which medicines are dispatched first.

Supplier oversight has become a recurring theme across Mexico's public health system this year. The federal government has launched a national platform to track medicine supply across IMSS, ISSSTE, IMSS-Bienestar, Birmex, and the Ministry of Health, aiming to identify supply gaps and generate compliance certificates for domestic and international suppliers. That report also noted that historic debts exceeding MX$40 billion (US$2.18 billion) and warehouse saturation at Birmex have contributed to delivery delays affecting multiple institutions, a structural challenge that extends beyond ISSSTE's own logistics network.

For medical unit administrators, the mechanism gives operational weight to timely shortage reporting, since data from pharmacies and warehouses is what triggers both redistribution and supplier follow-up. ISSSTE has not published data on the share of prescriptions filled in full, the average duration of shortages, or the minimum inventory levels set for each facility, information that would allow for an independent assessment of how the mechanism performs in practice.

ISSSTE says it will continue strengthening its logistics and supplier oversight mechanisms to support timely prescription fulfillment for its members. The institute frames this as an ongoing institutional priority, though several of the indicators needed to measure its results, including full versus partial fill rates and the time elapsed between a reported shortage and restocking, remain undisclosed. Distinguishing between central inventory shortfalls, supplier delays, and local distribution bottlenecks would clarify which interventions are most effective, since each cause implicates a different part of the procurement and logistics chain.